Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses Interim Results From Obesity Candidates and Advances in Treatment Approaches January 6, 2026 11:30 AM EST
Company Participants
Vincent Anzalone – Head of Investor Relations & VP
James Hamilton – Chief Medical Officer and Head of R&D
Dr. Christopher Anzalone – Chairman, CEO & President
Conference Call Participants
Carel le Roux
Prakhar Agrawal – Cantor Fitzgerald & Co., Research Division
Jason Gerberry – BofA Securities, Research Division
Luca Issi – RBC Capital Markets, Research Division
Madison Wynne El-Saadi – B. Riley Securities, Inc., Research Division
Mani Foroohar – Leerink Partners LLC, Research Division
Maurice Raycroft – Jefferies LLC, Research Division
Michael Ulz – Morgan Stanley, Research Division
Patrick Trucchio – H.C. Wainwright & Co, LLC, Research Division
Andrea Tan – Goldman Sachs Group, Inc., Research Division
Joseph Thome – TD Cowen, Research Division
William Pickering – Bernstein Institutional Services LLC, Research Division
Presentation
Operator
Good morning, and welcome to the Arrowhead Pharmaceuticals’ Virtual KOL event. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be available on the Arrowhead website following the event.
I’ll now turn the call over to Vincent Anzalone, Arrowhead’s Vice President of Finance and Investor Relations. Please go ahead, Vince.
Vincent Anzalone
Head of Investor Relations & VP
Thanks so much, Wilson, and thanks, everybody, for joining us today. We are excited to talk about our first interim results from our 2 obesity candidates, ARO-INHBE and ARO-ALK7. The press release went out this morning. So I’d like for all of you to refer to that. In addition, we will be making forward-looking statements today. So please refer to the risk factors in our SEC filings.
So what we’re trying to accomplish today is we have an external obesity and metabolic disease expert, Dr. Carel Le Roux, who will join us. He’s going to talk about what we see and what he
